Survodutide
Also known as: BI 456906
Survodutide is a dual glucagon and GLP-1 receptor agonist developed by Boehringer Ingelheim and Zealand Pharma, investigated for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH).
Key Findings at a Glance
- •Survodutide produced up to 14.9 percent mean weight loss at 46 weeks in Phase 2 obesity trials, with completers achieving 18.7 percent reduction, exceeding results typically seen with GLP-1-only agonists.
- •In a Phase 2 MASH trial published in NEJM, 62 percent of participants on survodutide 4.8 mg achieved MASH improvement without worsening fibrosis compared to 14 percent on placebo at 48 weeks.
- •The glucagon receptor component uniquely increases energy expenditure and directly reduces hepatic fat through enhanced lipid oxidation, providing mechanistic advantages over pure GLP-1 receptor agonists.
- •The Phase 3 SYNCHRONIZE program includes a cardiovascular outcomes trial enrolling nearly 5,000 participants to evaluate whether survodutide reduces major adverse cardiovascular events in people with obesity.
Survodutide Overview & Molecular Profile
Survodutide (BI 456906) is a novel dual agonist peptide that activates both the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R), developed through a collaboration between Boehringer Ingelheim and Zealand Pharma. The compound is designed to leverage the complementary metabolic effects of both receptors: GLP-1 receptor activation provides appetite suppression, glucose-dependent insulin secretion, and delayed gastric emptying, while glucagon receptor activation uniquely increases energy expenditure through hepatic glucose and lipid metabolism, thermogenesis, and direct reduction of hepatic fat content. This dual mechanism distinguishes survodutide from pure GLP-1 receptor agonists and positions it to address the full spectrum of metabolic disease including obesity, type 2 diabetes, and MASH. Phase 2 clinical trials have demonstrated up to 14.9% mean weight loss and significant improvements in liver histology in patients with MASH and fibrosis, and the Phase 3 SYNCHRONIZE program is currently evaluating survodutide for obesity and cardiovascular outcomes.
Mechanism of Action: Receptor Agonism & Metabolic Pathways
Survodutide engages two distinct receptor systems to produce its metabolic effects. As a GLP-1 receptor agonist, it stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release, delays gastric emptying, and activates central satiety pathways in the hypothalamus to reduce appetite and food intake. As a glucagon receptor agonist, it promotes hepatic glycogenolysis and gluconeogenesis, increases energy expenditure through thermogenic pathways, stimulates hepatic lipid oxidation and ketogenesis, and directly reduces hepatic fat accumulation. The glucagon receptor component provides a mechanistic advantage over pure GLP-1 agonists by directly targeting the liver, the central organ in metabolic homeostasis, enabling reduction of hepatic steatosis and potentially fibrosis independent of weight loss. The ratio of GLP-1 to glucagon receptor activity in survodutide is optimized to maintain glucose homeostasis despite the hyperglycemic potential of glucagon receptor activation, resulting in net improvements in both glycemic control and body weight.
Research-Observed Effects
Weight Loss
Phase 2 clinical trials have demonstrated dose-dependent and clinically significant weight loss with survodutide. In a randomized, double-blind, placebo-controlled dose-finding trial in 387 adults with obesity without diabetes, survodutide at the 4.8 mg dose produced mean weight loss of 14.9% at 46 weeks compared to 2.8% with placebo. Among participants who completed the maintenance phase on 4.8 mg, weight loss reached 18.7%. Approximately 82.8% of participants on the highest dose achieved at least 5% weight loss, and 54.7% achieved at least 15% loss. The superior weight loss compared to GLP-1-only agonists is attributed to the additional energy expenditure driven by glucagon receptor activation, which increases basal metabolic rate and promotes lipid oxidation.
MASH and Liver Fat Reduction
A Phase 2 randomized trial published in the New England Journal of Medicine evaluated survodutide in 293 adults with biopsy-confirmed MASH and fibrosis. At 48 weeks, 62% of participants on the 4.8 mg dose achieved MASH improvement without worsening of fibrosis compared to 14% on placebo. Liver fat reduction of at least 30% was achieved by 67% of participants on survodutide versus 14% on placebo, and fibrosis improvement of at least one stage was observed in 34-36% of treated participants. The direct hepatic effects are mediated through glucagon receptor-driven lipid oxidation and reduced de novo lipogenesis, providing a mechanistic advantage over therapies that rely solely on weight loss for liver benefit.
Glycemic Improvement
In Phase 2 trials in adults with type 2 diabetes, survodutide demonstrated dose-dependent reductions in HbA1c alongside significant weight loss. At doses up to 2.7 mg weekly, survodutide produced weight loss of up to 8.7% compared to 6.0% with semaglutide 1.0 mg, with comparable glycemic improvements. Despite the theoretical hyperglycemic effect of glucagon receptor activation, the net metabolic effect of survodutide is glucose-lowering due to the combined actions of enhanced insulin secretion, reduced hepatic insulin resistance from decreased liver fat, and overall weight reduction. The balanced dual agonism ensures that gluconeogenic effects of glucagon are offset by the insulinotropic and appetite-suppressive effects of GLP-1 receptor activation.
Energy Expenditure Enhancement
The glucagon receptor agonism component of survodutide provides a unique mechanism for increasing total energy expenditure, distinguishing it from pure GLP-1 receptor agonists. Preclinical studies in diet-induced obese mice demonstrated 25-27% body weight reduction through increased energy expenditure and lipid oxidation. Glucagon receptor activation stimulates hepatic thermogenesis, promotes brown adipose tissue activation, and increases amino acid catabolism, all contributing to elevated basal metabolic rate. This energy expenditure component helps explain the greater magnitude of weight loss observed with dual agonists compared to GLP-1-only therapies, as the metabolic cost of glucagon-driven pathways supplements the caloric deficit achieved through appetite suppression.
Cardiovascular Risk Factor Improvement
Clinical trials have documented improvements in multiple cardiovascular risk factors with survodutide treatment, including reductions in systolic blood pressure, triglycerides, and waist circumference. These improvements likely reflect both the direct metabolic effects of dual receptor agonism and the indirect benefits of substantial weight loss and hepatic fat reduction. The SYNCHRONIZE cardiovascular outcomes trial enrolling approximately 4,935 participants with established cardiovascular disease or chronic kidney disease is currently evaluating whether these risk factor improvements translate to reduced major adverse cardiovascular events. If positive, this would establish survodutide as both a weight management and cardiovascular risk reduction therapy.
Research Dosing Information
In clinical trials, survodutide is administered as a once-weekly subcutaneous injection with dose escalation to target doses of 2.4, 3.6, 4.8, or 6.0 mg. Phase 3 trials are evaluating the 3.6 mg and 6.0 mg doses with flexible titration protocols designed to optimize tolerability.
Note: Dosing information is provided for research reference only and is based on published studies using research subjects. This is not a recommendation for any use.
Research Studies & References
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
le Roux CW, Steen O, Lucas KJ, et al. (2024). eClinicalMedicine (The Lancet)
This Phase 2 dose-finding trial randomized 387 adults with overweight or obesity (BMI 27 or greater) without diabetes to one of five survodutide dose groups (0.6, 1.2, 1.8, 2.4, 3.6, or 4.8 mg weekly) or placebo for 46 weeks. The primary endpoint was percentage change in body weight from baseline. Survodutide demonstrated dose-dependent weight loss, with the 4.8 mg group achieving mean weight reduction of 14.9% compared to 2.8% with placebo at 46 weeks. Among completers in the highest dose group who maintained the 4.8 mg dose throughout, weight loss reached 18.7%. The proportion achieving at least 5% weight loss was 82.8% in the 4.8 mg group versus 26.9% with placebo, and 54.7% achieved at least 15% loss. Gastrointestinal adverse events including nausea, vomiting, and diarrhea were the most common side effects and occurred more frequently at higher doses. These results established survodutide as a promising dual agonist for obesity treatment and informed dose selection for the Phase 3 SYNCHRONIZE program.
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Sanyal AJ, Bedossa P, Fraessdorf M, et al. (2024). New England Journal of Medicine
This Phase 2 randomized, placebo-controlled trial evaluated survodutide in 293 adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis stages F1 through F3. Participants were randomized to survodutide at doses of 2.4, 4.8, or 6.0 mg weekly or placebo for 48 weeks, with paired liver biopsies performed at baseline and end of treatment. The primary endpoint was improvement in MASH without worsening of fibrosis, achieved by 47%, 62%, and 43% of participants in the 2.4, 4.8, and 6.0 mg groups respectively, compared to 14% with placebo. Liver fat reduction of at least 30% was observed in 63-67% of survodutide-treated participants. Fibrosis improvement of at least one stage occurred in 34-36% of treated participants compared to 22% with placebo. Gastrointestinal adverse events were the most common, with nausea reported by approximately 66% of survodutide-treated participants. These results represent the first demonstration of dual glucagon/GLP-1 agonist efficacy in MASH with fibrosis and support advancement to Phase 3 development.
The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection
Zimmermann T, Lim YC, Klatt KC, et al. (2024). Diabetes, Obesity and Metabolism
This preclinical characterization study describes the biomarker-guided selection strategy used to identify survodutide from 19 dual glucagon/GLP-1 receptor agonist candidates during development. Using diet-induced obese mouse models, the investigators demonstrated that optimized dual agonists produced 25-27% body weight reduction through increased energy expenditure and enhanced lipid oxidation, substantially exceeding the effects of GLP-1-only agonists. The study employed comprehensive pharmacokinetic and pharmacodynamic profiling including receptor binding assays, cAMP signaling studies, and in vivo efficacy assessments across multiple metabolic endpoints. Biomarker analysis identified key circulating markers that correlated with glucagon receptor engagement including increased amino acid catabolism and fibroblast growth factor 21 levels. The balanced receptor activation profile of survodutide was shown to produce synergistic metabolic benefits, with glucagon-driven energy expenditure complementing GLP-1-mediated appetite suppression. These findings provided the mechanistic foundation for clinical development and informed the dose selection strategy for human trials.
Frequently Asked Questions
Semaglutide (GLP-1)
C187H291N45O59
Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist that mimics the incretin hormone GLP-1, regulating blood glucose levels, appetite, and body weight through multiple metabolic pathways.
Tirzepatide (GLP-1/GIP)
C225H348N48O68
Tirzepatide is a first-in-class dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist, providing synergistic metabolic effects for diabetes and obesity research.
Retatrutide (Triple Agonist)
C221H342N46O68
Retatrutide is a first-in-class triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, producing the most profound metabolic effects seen in obesity research to date.